GSK3368715 (Synonyms: EPZ019997) |
Catalog No.GC36191 |
GSK3368715 (EPZ019997) est un inhibiteur de la protéine arginine méthyltransférase (PRMT) de type I actif par voie orale, réversible et S-adénosyl-L-méthionine (SAM) non compétitif (IC50 = 3,1 nM (PRMT1), 48 nM (PRMT3), 1148 nM ( PRMT4), 5,7 nM (PRMT6), 1,7 nM (PRMT8)). GSK3368715 (EPZ019997) produit un changement dans les états de méthylation de l'arginine, modifie l'utilisation des exons et possède une forte activité anticancéreuse.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1629013-22-4
Sample solution is provided at 25 µL, 10mM.
GSK3368715 (EPZ019997) is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50=3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)). GSK3368715 (EPZ019997) produces a shift in arginine methylation states, alters exon usage, and has strong anti-cancer activity[1]. IC50: 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), 1.7 nM (PRMT8)[1]Kiapp: 1.5 nM (PRMT1), 81 nM (PRMT3), 19 nM (PRMT4), 2.4 nM (PRMT6), 2 nM (PRMT8)[1]
GSK3368715 (EPZ019997) shows 50% or more growth inhibition relative to DMSO-treated cells in the majority of 249 cancer cell lines, representing 12 tumor types[1].
GSK3368715 (EPZ019997) significantly effects on the growth of BxPC3 xenografts at all doses tested, reducing tumor growth by 78% and 97% in the 150- and 300-mg/kg dose groups, respectively[1].
[1]. Fedoriw A, et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019 Jul 8;36(1):100-114.e25.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *